Emergent BioSolutions reported $1.82B in Assets for its fiscal quarter ending in December of 2023.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Akebia Therapeutics USD 342.13M 7.53M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
ANI Pharmaceuticals USD 1.57B 73.55M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Exelixis USD 2.51B 19.26M Sep/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Ironwood Pharmaceuticals USD 290.59M 5.46M Sep/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Lonza CHF 18.97B 164M Dec/2025
Merck USD 132.77B 2.97B Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Pacira USD 34.68B 33.44B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Sanofi EUR 130.29B 1.23B Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025